[206 Pages Report] Rising at a CAGR of 5.6% from 2022 to 2029, arthropod-borne viral infections testing demand is estimated to attain a valuation of US$ 1.3 Bn by end of the forecast period. The global Arthropod-Borne Viral Infections Testing Market is worth US$ 1.9 Bn in 2022.
| Attribute | Details |
|---|---|
| Arthropod-borne Viral Infections Testing Market Size (2022) | US$ 1.3 Bn |
| Predicted Net Worth (2029) | US$ 1.9 Bn |
| Global Market Growth Metrics (2022-2029) | 5.6% CAGR |
| Market Share of ELISA-based Tests | 52% |
Arboviral diseases are infections caused by virus spread among humans through the bites of arthropods. Common arthropods through which diseases are spread are mosquitoes and ticks. Arthropod-borne viral infections testing accounts for 4.4% of the global infectious disease diagnostics market, which stood at US$ 28 Bn in 2021.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 5.64% |
| H1, 2022 Projected | 5.63% |
| H1, 2022 Outlook | 3.83% |
| BPS Change - H1, 2022 (O) – H1, 2022 (P) | (-) 180 ↓ |
| BPS Change – H1, 2022 (O) – H1, 2021 | (-) 181 ↓ |
The variation between the BPS values observed within the arthropod-borne viral infections testing market in H1, 2022 - outlook over H1, 2022 projected reflects a decline by 180 BPS units. Additionally, a value BPS decline in H1-2022 over H1-2021 by 181 Basis Point Share (BPS) is demonstrated by the market.
The market observes a decline in the BPS values owed to the poor accessibility of detection methods in low-income economies with a large disease burden. As a result, high costs of healthcare facilities along with a lack of awareness about infectious diseases are expected to restrain the market's growth.
The market is subjected to several macro economical and industry variables, which include disease epidemiology, biologics licensing, product patenting and distribution licensing. Factors such as climate change, urbanization, and global trade can expand the geographic distribution of vectors and associated arboviruses, thus increasing the potential disease burden in susceptible hosts. This factor can present an opportunity for a positive growth outlook for the market
Healthcare has become an area of prime concern across the world and this is due to the rising diseases and infections across the world. There has been a substantial rise in arboviral diseases over the past few years and this has influenced demand for arthropod-borne viral infections testing.
Arthropod-borne viral infections testing demand rose at a CAGR of 4.9% from 2014 to 2021 and ended up with a market worth of US$ 1.2 Bn in 2021.
Most common arthropod-borne viral infection in the world according to WHO (World Health Organization) is dengue, with the potential risk to infect more than 30% of the world’s population.
Rising focus on public healthcare, increasing travel and trade activities on a global scale, changing lifestyle trends, environmental and climatic changes, rapid urbanization across the world, etc. are some major factors that influence arthropod-borne viral infections testing market potential on a global scale.
The market for arthropod-borne viral infections testing is anticipated to rise at a CAGR of 5.6% over the forecast period of 2022 to 2029.
“Re-emergence of Arthropod-borne Viral Infections to Drive Demand”
Arthropod-borne infections have proven to be responsible for widespread epidemics across the world. Some of the notable arboviral epidemics are of dengue and Zika virus which led to further complications in the population infected.
These epidemics have been dealt with to a certain extent but have proven their re-emergence in recent times which is a major factor that drives demand for arthropod-borne viral infections testing on a global level. The unpredictable nature of these infections promotes arthropod-borne viral infections testing providers to develop better diagnostic solutions to detect and avoid a community spread of these infections.
“Increasing Government Initiatives to Limit Risk of Arboviral Infections”
Governments across the world are working in sync with health organizations to mitigate the risk of arthropod-borne viral infections. As a matter of public safety, the focus on these diseases is increasing in the past few years with severe outbreaks being recorded across the world. The emergence of coronavirus in 2020 has further bolstered the importance of government inclusion in matters of public health.
“MEA and Latin America to Provide Major Opportunities for Market Players”
This FMI industry analysis provides metrics for the arthropod-borne viral infections testing market across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
The market for arthropod-borne viral infections testing in Latin America is anticipated to see high demand over the forecast period as it accounts for a notable number of infections across the world.
Developing healthcare infrastructure and rising awareness about arthropod-borne infections is anticipated to influence arthropod-borne viral infections testing demand in this region.
Demand for arthropod-borne viral infections testing in North America is expected to be low as the incidence of arboviral infections and diseases in this region is low. Advanced healthcare infrastructure and proper preventive care reduce the chances of infection in this region.
East Asia and South Asia are expected to see high demand for arthropod-borne viral infections testing over the forecast period. Implementation of stringent regulations to curb the spread of infectious diseases in this region is anticipated to drive market potential in these regions.
Densely populated countries like India and China are expected to emerge as highly lucrative markets for arthropod-borne viral infections testing vendors.
Rising instances of arboviral infections and epidemics in the MEA region are expected to majorly drive demand for arthropod-borne viral infections testing in this region. This region is expected to be one of the most important markets on a global level owing to the re-emergence of multiple infections like Zika virus and others.
Underdeveloped healthcare infrastructure is a major restraining factor for arthropod-borne viral infections testing market in the MEA region.
Principal Consultant
“Increasing Threat of Arboviral Infections Augmenting Market Expansion”
Instances of arthropod-borne viral infections have been increasing in the U.K. in recent times and this is anticipated to drive arthropod-borne viral infections testing demand in the nation. Lyme disease has become a prominent issue in the U.K. over recent years and other arthropod-borne diseases have also seen an increase in incidence.
Increasing global travel and trade are expected to fuel the adoption of arthropod-borne viral infections testing in the U.K.
“Developing Healthcare Infrastructure to Provide Lucrative Market Opportunities”
Brazil is anticipated to be a highly rewarding market for arthropod-borne viral infections testing vendors due to high incidence of multiple arthropod-borne viral infections like Zika virus and dengue. Brazil is a developing economy and has an emerging healthcare infrastructure that has a lot of untapped potential that arthropod-borne viral infections testing providers can unlock if they enter this market.
“High Preference for ELISA-based Test Kits to Drive Sales through 2029”
Enzyme-linked immunosorbent assay (ELISA)-based tests have been immensely popular in the arthropod-borne viral infections testing marketplace over the past few years and currently account for a dominant market share of 52% in the global landscape.
Increasing preference for use of ELISA-based test kits by patients, healthcare professionals, researchers, etc. is expected to propel its popularity further.
In 2022, reverse-transcription polymerase chain reaction (RT-PCR) kits hold a market share of 33.5% in the global arthropod-borne viral infections testing industry. The COVID-19 pandemic boosted demand for RT-PCR test kits and this trend is expected to be prevalent over the forecast period as well.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The COVID-19 pandemic invigorated demand for arthropod-borne viral infections testing and revolutionized our view on infectious diseases and infections. Increasing uncertainties in these diseases and their re-emergence are anticipated to play a major role in the coming years.
Sales of arthropod-borne viral infections testing kits dropped in 2020 as lockdown mandates were put in place and supply and logistic chains were disrupted. The market is expected to make a steady recovery in the post-pandemic era as restrictions are lifted across the world.
Arthropod-borne viral infections testing providers are investing in the research and development of rapid test kits that are effective in diagnosing infections in a short period of time with minimal error.
| Attribute | Details |
|---|---|
| Forecast Period | 2022-2029 |
| Historical Data Available for | 2014-2021 |
| Market Analysis | US$ Mn for Value |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
Arthropod-borne Viral Infections Testing Market by Test Type:
Arthropod-borne Viral Infections Testing Market by End User:
Arthropod-borne Viral Infections Testing Market by Region:
The global arthropod-borne viral infections testing market holds a valuation of US$ 1.3 Bn in 2022.
ELISA-based tests account for 52% of the global arthropod-borne viral infections testing market share.
Demand for arthropod-borne viral infections testing is predicted to evolve at a CAGR of 5.6% from 2022 to 2029.
Sales of arthropod-borne viral infections testing kits are projected to reach US$ 1.9 Bn by 2029.
Leading arthropod-borne viral infections testing companies are Roche Molecular Systems Inc., bioMérieux SA, InBios International Inc., NovaTec Immundiagnostica GmbH, Euroimmun AG (Sub. PerkinElmer), Quest Diagnostics, Certest Biotec S.L., Response Biomedical Corp., Chembio Diagnostic Systems Inc., and Abbott Laboratories.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Technology Roadmap 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 3.3. Macro-Economic Factors 4. Key Success Factors 4.1. Product Adoption / Usage Analysis 4.2. Disease Epidemiology, By Key countries 4.3. Strategic Promotional Strategies 4.4. Regulatory Scenario 4.5. Opportunity Analysis 5. Global Arthropod-borne Viral Infections Testing Market Demand Analysis 2014-2021 and Forecast, 2022-2029 5.1. Historical Market Volume (Mn Units) Analysis, 2014-2021 5.2. Current and Future Market Volume (Mn Units) Projections, 2022-2029 5.3. Y-o-Y Growth Trend Analysis 6. Global Arthropod-borne Viral Infections Testing Market - Pricing Analysis 6.1. Regional Pricing Analysis By Test Type 6.2. Pricing Break-up 6.2.1. Manufacturer Level Pricing 6.2.2. Distributor Level Pricing 6.3. Global Average Pricing Analysis Benchmark 7. Global Arthropod-borne Viral Infections Testing Market Demand (in Value or Size in US$ Mn) Analysis 2014-2021 and Forecast, 2022-2029 7.1. Historical Market Value (US$ Mn) Analysis, 2014-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2029 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Market Background 8.1. Macro-Economic Factors 8.1.1. Global GDP Growth Outlook 8.1.2. Global Internet Penetration Outlook 8.1.3. Global Media and Entertainment Industry Outlook 8.2. Forecast Factors - Relevance & Impact 8.2.1. Top Companies Historical Growth 8.2.2. Global Healthcare Industry Outlook 8.2.3. Global GDP Growth Outlook 8.2.4. Research and Developmental Activities 8.2.5. Global Diagnostic Industry Outlook 8.3. Value Chain 8.4. Market Dynamics 8.4.1. Drivers 8.4.2. Restraints 8.4.3. Opportunity Analysis 9. Global Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029, by Test Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) and Volume Analysis By Test Type, 2014-2021 9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Test Type, 2021 - 2021 9.3.1. ELISA-based Tests 9.3.2. RT-PCR based Tests 9.3.3. Immunochromatography Rapid Diagnosis 9.4. Market Attractiveness Analysis By Test Type 10.Global Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029, by End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) and Volume Analysis By End User, 2014-2021 10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By End User, 2021 - 2021 10.3.1. Hospitals 10.3.2. Public Health Laboratory 10.3.3. Diagnostic Centers 10.3.4. Others 10.4. Market Attractiveness Analysis By End User 11.Global Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) and Volume Analysis By Region, 2014-2021 11.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast By Region, 2021 - 2021 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. Middle East and Africa (MEA) 11.3.5. East Asia 11.3.6. South Asia 11.3.7. Oceania 11.4. Market Attractiveness Analysis By Region 12. North America Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021 12.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029 12.4.1.By Country 12.4.1.1. U.S. 12.4.1.2. Canada 12.4.2. By Test Type 12.4.3. By End User 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Test Type 12.5.3. By End User 12.6. Market Trends 12.7. Key Market Participants - Intensity Mapping 12.8. Drivers and Restraints - Impact Analysis 13. Latin America Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021 13.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029 13.4.1.By Country 13.4.1.1. Brazil 13.4.1.2. Mexico 13.4.1.3. Rest of Latin America 13.4.2. By Test Type 13.4.3. By End User 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Test Type 13.5.3. By End User 13.6. Market Trends 13.7. Key Market Participants - Intensity Mapping 13.8. Drivers and Restraints - Impact Analysis 14.Europe Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021 14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029 14.4.1.By Country 14.4.1.1. Germany 14.4.1.2. Italy 14.4.1.3. France 14.4.1.4. U.K. 14.4.1.5. Spain 14.4.1.6. BENELUX 14.4.1.7. Russia 14.4.1.8. Rest of Europe 14.4.2. By Test Type 14.4.3. By End User 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Test Type 14.5.3. By End User 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 15.South Asia Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021 15.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029 15.4.1.By Country 15.4.1.1. India 15.4.1.2. Thailand 15.4.1.3. Indonesia 15.4.1.4. Malaysia 15.4.1.5. Rest of South Asia 15.4.2. By Test Type 15.4.3. By End User 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Test Type 15.5.3. By End User 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16.East Asia Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021 16.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029 16.4.1.By Country 16.4.1.1. China 16.4.1.2. Japan 16.4.1.3. South Korea 16.4.2. By Test Type 16.4.3. By End User 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Test Type 16.5.3. By End User 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17.Oceania Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021 17.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029 17.4.1.By Country 17.4.1.1. Australia 17.4.1.2. New Zealand 17.4.2. By Test Type 17.4.3. By End User 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Test Type 17.5.3. By End User 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 18.Middle East and Africa Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029 18.1. Introduction 18.2. Pricing Analysis 18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021 18.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029 18.4.1. By Country 18.4.1.1. GCC Countries 18.4.1.2. Turkey 18.4.1.3. Northern Africa 18.4.1.4. South Africa 18.4.1.5. Rest of Middle East and Africa 18.4.2. By Test Type 18.4.3. By End User 18.5. Market Attractiveness Analysis 18.5.1. By Country 18.5.2. By Test Type 18.5.3. By End User 18.6. Market Trends 18.7. Key Market Participants - Intensity Mapping 18.8. Drivers and Restraints - Impact Analysis 19. Key and Emerging Countries Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Arthropod-borne Viral Infections Testing Market Analysis 19.2.1. By Test Type 19.2.2. By End User 19.3. Canada Arthropod-borne Viral Infections Testing Market Analysis 19.3.1. By Test Type 19.3.2. By End User 19.4. Mexico Arthropod-borne Viral Infections Testing Market Analysis 19.4.1. By Test Type 19.4.2. By End User 19.5. Brazil Arthropod-borne Viral Infections Testing Market Analysis 19.5.1. By Test Type 19.5.2. By End User 19.6. U.K. Arthropod-borne Viral Infections Testing Market Analysis 19.6.1. By Test Type 19.6.2. By End User 19.7. Germany Arthropod-borne Viral Infections Testing Market Analysis 19.7.1. By Test Type 19.7.2. By End User 19.8. France Arthropod-borne Viral Infections Testing Market Analysis 19.8.1. By Test Type 19.8.2. By End User 19.9. Italy Arthropod-borne Viral Infections Testing Market Analysis 19.9.1. By Test Type 19.9.2. By End User 19.10. Spain Arthropod-borne Viral Infections Testing Market Analysis 19.10.1. By Test Type 19.10.2. By End User 19.11. BENELUX Arthropod-borne Viral Infections Testing Market Analysis 19.11.1. By Test Type 19.11.2. By End User 19.12. Russia Arthropod-borne Viral Infections Testing Market Analysis 19.12.1. By Test Type 19.12.2. By End User 19.13. China Arthropod-borne Viral Infections Testing Market Analysis 19.13.1. By Test Type 19.13.2. By End User 19.14. Japan Arthropod-borne Viral Infections Testing Market Analysis 19.14.1. By Test Type 19.14.2. By End User 19.15. South Korea Arthropod-borne Viral Infections Testing Market Analysis 19.15.1. By Test Type 19.15.2. By End User 19.16. India Arthropod-borne Viral Infections Testing Market Analysis 19.16.1. By Test Type 19.16.2. By End User 19.17. ASEAN Arthropod-borne Viral Infections Testing Market Analysis 19.17.1. By Test Type 19.17.2. By End User 19.18. Australia Arthropod-borne Viral Infections Testing Market Analysis 19.18.1. By Test Type 19.18.2. By End User 19.19. New Zealand Arthropod-borne Viral Infections Testing Market Analysis 19.19.1. By Test Type 19.19.2. By End User 19.20. GCC Countries Arthropod-borne Viral Infections Testing Market Analysis 19.20.1. By Test Type 19.20.2. By End User 19.21. Turkey Arthropod-borne Viral Infections Testing Market Analysis 19.21.1. By Test Type 19.21.2. By End User 19.22. South Africa Arthropod-borne Viral Infections Testing Market Analysis 19.22.1. By Test Type 19.22.2. By End User 20.Market Structure Analysis 20.1. Market Analysis by Tier of Companies (Arbovirus Testing) 20.2. Market Concentration 20.3. Market Share Analysis of Top Players 20.4. Market Presence Analysis 20.4.1. By Regional footprint of Players 20.4.2. Product foot print by Players 20.4.3. Channel Foot Print by Players 21.Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Thermo Fisher Scientific, Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Strategy Overview 21.3.1.5.1. Marketing Strategy 21.3.1.5.2. Product Strategy 21.3.1.5.3. Channel Strategy 21.3.2. Roche Molecular Systems Inc. 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Strategy Overview 21.3.2.5.1. Marketing Strategy 21.3.2.5.2. Product Strategy 21.3.2.5.3. Channel Strategy 21.3.3. bioMérieux SA 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Strategy Overview 21.3.3.5.1. Marketing Strategy 21.3.3.5.2. Product Strategy 21.3.3.5.3. Channel Strategy 21.3.4. Abbott Laboratories 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Strategy Overview 21.3.4.5.1. Marketing Strategy 21.3.4.5.2. Product Strategy 21.3.4.5.3. Channel Strategy 21.3.5. InBios International, Inc. 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Strategy Overview 21.3.5.5.1. Marketing Strategy 21.3.5.5.2. Product Strategy 21.3.5.5.3. Channel Strategy 21.3.6. NovaTec Immundiagnostica GmbH 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Strategy Overview 21.3.6.5.1. Marketing Strategy 21.3.6.5.2. Product Strategy 21.3.6.5.3. Channel Strategy 21.3.7. Euroimmun AG (Sub. PerkinElmer) 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Strategy Overview 21.3.7.5.1. Marketing Strategy 21.3.7.5.2. Product Strategy 21.3.7.5.3. Channel Strategy 21.3.8. Quest Diagnostics 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Profitability by Market Segments (Product/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Strategy Overview 21.3.8.5.1. Marketing Strategy 21.3.8.5.2. Product Strategy 21.3.8.5.3. Channel Strategy 21.3.9. Certest Biotec S.L. 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Profitability by Market Segments (Product/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Strategy Overview 21.3.9.5.1. Marketing Strategy 21.3.9.5.2. Product Strategy 21.3.9.5.3. Channel Strategy 21.3.10. Response Biomedical Corp. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Profitability by Market Segments (Product/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Strategy Overview 21.3.10.5.1. Marketing Strategy 21.3.10.5.2. Product Strategy 21.3.10.5.3. Channel Strategy 21.3.11. Chembio Diagnostic Systems, Inc. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Profitability by Market Segments (Product/Channel/Region) 21.3.11.4. Sales Footprint 21.3.11.5. Strategy Overview 21.3.11.5.1. Marketing Strategy 21.3.11.5.2. Product Strategy 21.3.11.5.3. Channel Strategy 22.Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Arthropod-borne Viral Infections Testing Market
